Company logo

BSX - Boston Scientific Corporation

NYSE -> Healthcare -> Medical Devices
Marlborough, United States
Type: Equity

BSX price evolution
BSX
(in millions $) 31 Jan 2024 30 Sep 2023 30 Jul 2023 31 Mar 2023
Current assets
Cash $865 $952 $426 $570
Short term investments
Net receivables $2228 $2101 $2134 $2076
Inventory $2484 $2404 $2250 $2050
Total current assets $6514 $6504 $5886 $5704
Long term investments
Property, plant & equipment $2859 $2635 $2534 $2478
Goodwill & intangible assets $20390 $19457 $19722 $19329
Total noncurrent assets $28622 $27539 $27715 $27188
Total investments
Total assets $35136 $34043 $33601 $32892
Current liabilities
Accounts payable $942 $929 $899 $868
Deferred revenue
Short long term debt $531 $513 $559 $510
Total current liabilities $4933 $4579 $4562 $4083
Long term debt $8571 $8386 $8494 $8495
Total noncurrent liabilities $10673 $10335 $10554 $10700
Total debt $9102 $8899 $9053 $9005
Total liabilities $15606 $14914 $15116 $14783
Shareholders' equity
Retained earnings $819 $315 -$189 -$450
Other shareholder equity $49 $231 $208 $178
Total shareholder equity $19282 $18886 $18226 $17850
(in millions $) 31 Jan 2024 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $865 $928 $1925 $1734
Short term investments
Net receivables $2228 $1970 $1778 $1531
Inventory $2484 $1867 $1610 $1351
Total current assets $6514 $5760 $6317 $6694
Long term investments
Property, plant & equipment $2859 $2832 $2252 $2084
Goodwill & intangible assets $20390 $18822 $18109 $15868
Total noncurrent assets $28622 $26709 $25912 $24083
Total investments
Total assets $35136 $32469 $32229 $30777
Current liabilities
Accounts payable $942 $862 $794 $513
Deferred revenue
Short long term debt $531 $20 $261 $13
Total current liabilities $4933 $3803 $4274 $3681
Long term debt $8571 $8915 $8804 $9130
Total noncurrent liabilities $10673 $11093 $11333 $11770
Total debt $9102 $8935 $9065 $9143
Total liabilities $15606 $14896 $15607 $15451
Shareholders' equity
Retained earnings $819 -$750 -$1392 -$2378
Other shareholder equity $49 $268 $263 $207
Total shareholder equity $19282 $17573 $16622 $15326
(in millions $) 31 Jan 2024 30 Sep 2023 30 Jul 2023 31 Mar 2023
Revenue
Total revenue $3725 $3527 $3389
Cost of revenue $1101 $1040
Gross Profit $2567 $2426 $2349
Operating activities
Research & development $356 $337
Selling, general & administrative $1242 $1215
Total operating expenses $1964 $1734 $1798
Operating income $692 $551
Income from continuing operations
EBIT $675 $510
Income tax expense $1 $105 $131
Interest expense -$65 $66 $65
Net income
Net income $504 $504 $314
Income (for common shares) $505 $300
(in millions $) 31 Jan 2024 31 Dec 2022 31 Jan 2022 31 Dec 2020
Revenue
Total revenue $14240 $12682 $9913
Cost of revenue $3956 $3465
Gross Profit $9849 $8726 $6448
Operating activities
Research & development $1323 $1143
Selling, general & administrative $4520 $3787
Total operating expenses $7490 $7079 $6527
Operating income $1647 -$79
Income from continuing operations
EBIT $1610 $281
Income tax expense $393 $443 $2
Interest expense -$265 $470 $361
Net income
Net income $1570 $697 -$82
Income (for common shares) $642 -$115
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income $505 $504 $270 $314
Operating activities
Depreciation $313 $300 $298 $285
Business acquisitions & disposals -$793 -$16 -$706 -$385
Stock-based compensation $59 $59 $60 $55
Total cash flows from operations $957 $698 $658 $190
Investing activities
Capital expenditures -$260 -$182 -$136 -$99
Investments $2
Total cash flows from investing -$1053 -$197 -$840 -$484
Financing activities
Dividends paid
Sale and purchase of stock $15 $73 $25 $13
Net borrowings -$41 $37
Total cash flows from financing $15 $16 $43 -$69
Effect of exchange rate $8 -$5 -$3
Change in cash and equivalents -$77 $513 -$143 -$363
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income $1593 $697 $1040 -$82
Operating activities
Depreciation $1196 $1136 $1093 $1123
Business acquisitions & disposals -$1900 -$1561 -$1153 $12
Stock-based compensation $233 $220 $194 $170
Total cash flows from operations $2503 $1526 $1870 $1508
Investing activities
Capital expenditures -$677 -$506 -$458 -$277
Investments $2 $56 $15
Total cash flows from investing -$2574 -$2011 -$1597 -$411
Financing activities
Dividends paid -$28
Sale and purchase of stock $126 $83 $60 $492
Net borrowings -$4 -$165 -$999
Total cash flows from financing $5 -$548 -$95 $293
Effect of exchange rate -$2
Change in cash and equivalents -$70 -$1042 $173 $1388
Fundamentals
Market cap $100.58B
Enterprise value $108.81B
Shares outstanding 1.47B
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q 14.90%
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio 5.23
Book/Share 13.12
Cash/Share 0.59
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 0.81
Net debt/EBITDA N/A
Current ratio 1.32
Quick ratio 0.82